These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16480325)

  • 1. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective.
    Chatal JF
    Cancer Biother Radiopharm; 2006 Feb; 21(1):1-4. PubMed ID: 16480325
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
    Frølund UC; Hansen PB
    Ugeskr Laeger; 2011 May; 173(20):1417-21. PubMed ID: 21586245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373026
    [No Abstract]   [Full Text] [Related]  

  • 8. [New trends in non-Hodgkin's lymphoma therapy].
    Mazur G; Wróbel T; Jurczak W; Butrym A
    Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
    Hagenbeek A
    Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512
    [No Abstract]   [Full Text] [Related]  

  • 10. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma.
    Focosi D; Cecconi N; Boni G; Orciuolo E; Galimberti S; Petrini M
    Hematol Oncol; 2008 Sep; 26(3):179-81. PubMed ID: 18383187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment.
    Peyrade F; Italiano A; Fontana X; Peyrottes I; Thyss A
    Lancet Oncol; 2007 Sep; 8(9):849-50. PubMed ID: 17765194
    [No Abstract]   [Full Text] [Related]  

  • 14. Preface on follicular non-Hodgkin's lymphoma.
    Hagenbeek A
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):93. PubMed ID: 21658610
    [No Abstract]   [Full Text] [Related]  

  • 15. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.
    Porrata LF; Ristow K; Witzig TE; Tuinistra N; Habermann TM; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Markovic SN
    Leukemia; 2007 Dec; 21(12):2554-6. PubMed ID: 17581607
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioimmunotherapy of Non-Hodgkin's lymphoma.
    Britton KE
    J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
    [No Abstract]   [Full Text] [Related]  

  • 17. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
    Goldenberg DM; Sharkey RM
    J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
    [No Abstract]   [Full Text] [Related]  

  • 18. Haematological cancer: Radioimmunotherapy--time to be upfront and fractionated?
    Razzak M
    Nat Rev Clin Oncol; 2014 Feb; 11(2):68. PubMed ID: 24343668
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab).
    Cooney J; Stiff P; Kaminski M
    Bone Marrow Transplant; 2002 Mar; 29(6):523-5. PubMed ID: 11960274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of follicular lymphoma in the era of monoclonal antibodies.
    Coiffier B
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):484-91, 505. PubMed ID: 16167027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.